Hetero Labs Limited

Hetero Labs Limited - pharma in Balanagar, Telangana, India. FY 2026 financials and compliance.
CIN U24110TG1989PLC009723 Incorporated 10 March 1989 ROC Hyderabad HQ Balanagar, Telangana, India
Active Public Limited Company pharma
Data last updated
Revenue · FY 2025
₹16,537 Cr
▲ 13.00% YoY
EBITDA · FY 2025
*****
▲ 18.00% YoY
Net profit · FY 2025
*****
▲ 56.00% YoY
Authorised capital
₹320 Cr
Registered with MCA
Paid-up capital
₹277.06 Cr
Issued & subscribed
Open charges
₹6,736.19 Cr
Satisfied ₹13,851 Cr
Company age
37 yrs
Est. 1989
Employees · EPFO
7,319
Latest available

About Hetero Labs Limited

Data last updated: 25 February 2026

Hetero Labs Limited is a public limited company based in Balanagar, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 10 March 1989, the company has been in operation for over 37 years.

Registered with ROC Hyderabad under CIN U24110AP1989PLC009723.

Capital: an authorised share capital of ₹320 Cr and a paid-up capital of ₹277.06 Cr. Formerly known as Permila Drugs Private Limited and Hetero Drugs Private Limited. It is led by directors including Bandi Vamsikrishna and Govindaraju Bhavani.

Last AGM: 11 September 2025. Financial statements filed for year ended 31 March 2025. Office: Balanagar, Telangana.

As per the financials filed for FY 2025, the company reported a revenue of ₹16,537 Cr, a growth of 13% compared to the previous year.

The company has a workforce of approximately 7,319 employees as per the latest available data.

The company is associated with 1 brand - Hetero. As per MCA filings, the company has open charges of ₹6,736.19 Cr and satisfied charges of ₹13,851 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hetero.com.

Company Details of Hetero Labs Limited
CIN U24110TG1989PLC009723
Registration Number 009723
Incorporation Date 10 March 1989
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 11 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Bandi Vamsikrishna Managing Director Attunuri Venkatanarasa Reddy Whole-Time Director Mohana Reddy Chilukuri Whole-Time Director
Contact Details
  • Email
    **************
  • Telephone
    **************
  • Website
    **************
  • Social Media
  • Registered Address
    #7 – 2 – A2, Industrial Estate Sanath Nagar, Balanagar, Telangana, India – 500018
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Company report
Hetero Labs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Hetero Labs Limited report

Financials, compliance, directors, charges, ownership and filings for Hetero Labs Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Hetero Labs Limited

Hetero Labs Limited has undergone 3 name changes throughout its history. The company was previously known as Permila Drugs Private Limited, Hetero Drugs Private Limited, and Pharmasia Laboratory Private Limited. The current legal name is Hetero Labs Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Hetero Labs Limited Current
Permila Drugs Private Limited Previous
Hetero Drugs Private Limited Previous
Pharmasia Laboratory Private Limited Previous

CIN History of Hetero Labs Limited

Hetero Labs Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24110TG1989PLC009723, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
U24110TG1989PLC009723 Current
U24110AP1989PLC009723 Previous
L24110AP1989PLC009723 Previous

Associated Brands with Hetero Labs Limited

Hetero Labs Limited operates one associated brand: Hetero. These brands represent Hetero Labs Limited's diversified market presence and brand portfolio.

Brand Description Website
Hetero
Hetero is recognized as a leading global pharmaceutical company based in India. hetero.com

Competitors & Alternatives of Hetero Labs Limited

Brands and companies operating in the same space as Hetero Labs Limited include Merck, Roivant Sciences, AbbVie and 7 more.

Competitor Description Location Founded
Merck Merck Pharmaceutical products are manufactured and marketed worldwide. Kenilworth, United Kingdom, United Kingdom 1891
Roivant Sciences Roivant Sciences Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. New York, United States, United States 2014
AbbVie AbbVie Biopharmaceutical research and drug development are conducted globally by AbbVie. Chicago, United States, United States 2012
Lilly Lilly Traditional pharmaceutical medicines are developed for multiple health fields. United States 1876
Gilead Gilead Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others Foster City, United States, United States 1987
United Therapeutics United Therapeutics Treatments for chronic and life-threatening diseases are developed and commercialized. Silver Spring, United States, United States 1998
Roche Roche Pharmaceuticals and diagnostics kits are developed for various diseases. Basel, Switzerland, Switzerland 1896
Ascendis Pharma Ascendis Pharma Long-acting prodrug therapies are developed for endocrine and rare diseases. Hellerup, Denmark, Denmark 2007
MorphoSys MorphoSys Therapeutic antibodies for cancer and other diseases are developed. Planegg, Germany, Germany 1992
Vertex Pharmaceuticals Vertex Pharmaceuticals Developer of drugs for the treatment of multiple disorders United States 1989

Business Activity of Hetero Labs Limited

Hetero Labs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Board of Directors of Hetero Labs Limited

Hetero Labs Limited is currently managed by 9 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Bandi Vamsikrishna
Also directs: Allita Finvest And Advisors Llp, Eliana Investments And Holdings Llp, Krishn Capital Advisors Llp and 5 more
Managing Director 10 Apr 2008 18 Years 3 Months Current
Govindaraju Bhavani
Also directs: Hetero Biopharma Limited, Annora Pharma Private Limited
Director 11 Aug 2023 2 Years 11 Months Current
Parthasaradhi Reddy Bandi
Also directs: Allita Finvest And Advisors Llp, Eliana Investments And Holdings Llp, Krishn Capital Advisors Llp and 5 more
Director 01 Apr 2021 5 Years 3 Months Current
Srinivas Reddy Male
Also directs: Krishna Sahithi Reddy Properties Llp, Krishna Karthikeya Reddy Properties Llp, Hhc Pharma Llp and 5 more
Director 25 Sep 2008 17 Years 9 Months Current
Attunuri Venkatanarasa Reddy
Also directs: Hetero Drugs Limited
Whole-Time Director 02 Jun 2014 12 Years 1 Months Current
Sujesh Vasudevan
Also directs: Eris Lifesciences Limited, Entero Healthcare Solutions Limited, Eris Therapeutics Limited
Director 22 Feb 2024 2 Years 4 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Hetero Labs Limited FY 2025 filings available

Hetero Labs Limited reported revenue of ₹16,537 Cr (up 13% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue
₹16,537 Cr ▲ 13%
Profit
***** ▲ 56%
EBITDA
***** ▲ 18%
Metrics
*****
*****
*****
*****
*****
Revenue
Revenue from Operations
*****
*****
*****
*****
*****
Revenue Growth %
*****
*****
*****
*****
*****
Other Income
*****
*****
*****
*****
*****
Total Revenue
*****
*****
*****
*****
*****
Expenses
Total Expenses
*****
*****
*****
*****
*****
Raw Material Cost
*****
*****
*****
*****
*****
Change in Inventory FG
*****
*****
*****
*****
*****
Change in Inventory WIP
*****
*****
*****
*****
*****
Purchase of Traded Goods
*****
*****
*****
*****
*****
Employee Cost
*****
*****
*****
*****
*****
Managerial Remuneration
*****
*****
*****
*****
*****
Audit Fees
*****
*****
*****
*****
*****
Insurance
*****
*****
*****
*****
*****
Power & Fuel
*****
*****
*****
*****
*****
Interest
*****
*****
*****
*****
*****
Depreciation
*****
*****
*****
*****
*****
Other Expenses
*****
*****
*****
*****
*****
Profitability
EBITDA (Operating Profit)
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
Exceptional Items
*****
*****
*****
*****
*****
Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Exceptional & Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Tax
*****
*****
*****
*****
*****
Tax & Net Profit
Tax Expense
*****
*****
*****
*****
*****
Current Tax
*****
*****
*****
*****
*****
Deferred Tax
*****
*****
*****
*****
*****
Profit from Discontinued Operations
*****
*****
*****
*****
*****
Tax on Discontinued Operations
*****
*****
*****
*****
*****
Profit
*****
*****
*****
*****
*****
Net Margin %
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Shareholders' Funds
Total Shareholders' Funds
*****
*****
*****
*****
*****
Equity Capital
*****
*****
*****
*****
*****
Reserves & Surplus
*****
*****
*****
*****
*****
Money Against Warrants
*****
*****
*****
*****
*****
Other Equity
*****
*****
*****
*****
*****
Non-Current Liabilities
Total Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Borrowings
*****
*****
*****
*****
*****
Deferred Tax Liabilities
*****
*****
*****
*****
*****
Other Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Provisions
*****
*****
*****
*****
*****
Current Liabilities
Total Current Liabilities
*****
*****
*****
*****
*****
Short-Term Borrowings
*****
*****
*****
*****
*****
Trade Payables
*****
*****
*****
*****
*****
Other Current Liabilities
*****
*****
*****
*****
*****
Short-Term Provisions
*****
*****
*****
*****
*****
Total Equity & Liabilities
*****
*****
*****
*****
*****
Non-Current Assets
Non-Current Assets
*****
*****
*****
*****
*****
Tangible Assets
*****
*****
*****
*****
*****
Intangible Assets
*****
*****
*****
*****
*****
Capital WIP
*****
*****
*****
*****
*****
Intangibles Under Dev
*****
*****
*****
*****
*****
Investments
*****
*****
*****
*****
*****
Deferred Tax Assets
*****
*****
*****
*****
*****
LT Loans & Advances
*****
*****
*****
*****
*****
Other Non-Current Assets
*****
*****
*****
*****
*****
Current Assets
Current Assets
*****
*****
*****
*****
*****
Current Investments
*****
*****
*****
*****
*****
Inventories
*****
*****
*****
*****
*****
Trade Receivables
*****
*****
*****
*****
*****
Cash & Bank Balance
*****
*****
*****
*****
*****
ST Loans & Advances
*****
*****
*****
*****
*****
Other Current Assets
*****
*****
*****
*****
*****
Total Assets
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Cash from Operating Activities (CFO)
Profit Before Tax
*****
*****
*****
*****
*****
Non-Cash Adjustments
*****
*****
*****
*****
*****
+ Interest Expense
*****
*****
*****
*****
*****
+ Depreciation
*****
*****
*****
*****
*****
+/- Unrealized Forex
*****
*****
*****
*****
*****
- Dividend Income
*****
*****
*****
*****
*****
- Interest Income
*****
*****
*****
*****
*****
+/- Other Non-Cash Items
*****
*****
*****
*****
*****
Changes in Working Capital
*****
*****
*****
*****
*****
+/- Inventory
*****
*****
*****
*****
*****
+/- Debtors
*****
*****
*****
*****
*****
+/- Creditors
*****
*****
*****
*****
*****
Reconciliation Adjustments
*****
*****
*****
*****
*****
Cash Generated from Operations
*****
*****
*****
*****
*****
Income Taxes Paid
*****
*****
*****
*****
*****
Net CFO (Cash from Operations)
*****
*****
*****
*****
*****
Cash from Investing Activities (CFI)
Acquisitions & Disposals
*****
*****
*****
*****
*****
Disposal of Subsidiaries
*****
*****
*****
*****
*****
Acquisition of Subsidiaries
*****
*****
*****
*****
*****
Capex
*****
*****
*****
*****
*****
Purchase of Fixed Assets
*****
*****
*****
*****
*****
Sale of Fixed Assets
*****
*****
*****
*****
*****
Other Investing Cash Flows
*****
*****
*****
*****
*****
Net CFI (Cash from Investing)
*****
*****
*****
*****
*****
Cash from Financing Activities (CFF)
Equity Issuance
*****
*****
*****
*****
*****
Debt Raised
*****
*****
*****
*****
*****
Debt Repaid
*****
*****
*****
*****
*****
Dividends Paid
*****
*****
*****
*****
*****
Interest Paid
*****
*****
*****
*****
*****
Net CFF (Cash from Financing)
*****
*****
*****
*****
*****
Net Cash Position
Net Change in Cash (Pre-Forex)
*****
*****
*****
*****
*****
Closing Cash & Equivalents
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Liquidity
Current Ratio
*****
*****
*****
*****
*****
Quick Ratio
*****
*****
*****
*****
*****
Cash Ratio
*****
*****
*****
*****
*****
Efficiency
Inventory Days
*****
*****
*****
*****
*****
Debtor Days
*****
*****
*****
*****
*****
Creditor Days
*****
*****
*****
*****
*****
Cash Conversion Cycle
*****
*****
*****
*****
*****
Asset Turnover
*****
*****
*****
*****
*****
Profitability
Net Profit Margin %
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
ROE %
*****
*****
*****
*****
*****
ROCE %
*****
*****
*****
*****
*****
Net Worth Margin %
*****
*****
*****
*****
*****
Growth
Revenue Growth %
*****
*****
*****
*****
*****
Leverage
Equity Multiplier
*****
*****
*****
*****
*****
Debt / EBITDA
*****
*****
*****
*****
*****
Solvency
D/E Ratio
*****
*****
*****
*****
*****
ICR
*****
*****
*****
*****
*****

Consolidated Statements

Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.

Unlock Complete Financial History (FY 2015 – Latest)
Standalone & Consolidated - Income Statement, Balance Sheet, Cash Flow, Financial Ratios and Growth Trends with 10+ years of line-item data.
10+ years of data Line-item breakdown Balance Sheet detail Cash Flow analysis 20+ ratios & metrics Downloadable PDF

Charges & Borrowings of Hetero Labs Limited

Open charges
₹6,736.19 Cr
Satisfied charges
₹13,851 Cr
Breakdown by lending institutions
Idbi Trusteeship Services Limited₹4,990.00 Cr
State Bank of India₹1,200.41 Cr
Others₹540.95 Cr
Bank of India₹4.83 Cr
Latest charge details
DateLenderAmountStatus
31 Jan 2026 Others ₹30.22 Lakh Open
23 Jan 2026 Others ₹15.14 Lakh Open
31 Dec 2025 Others ₹9.8 Lakh Open
30 Dec 2025 Others ₹64 Lakh Open
20 Dec 2025 Others ₹20.16 Lakh Open

Total charge records: 169 View all charges

Employees and EPFO Compliance at Hetero Labs Limited

View historical data on people associated with Hetero Labs Limited, including employment history and EPFO contributions.

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Hetero Labs Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Hetero Labs Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Hetero Labs Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Hetero Labs Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Hetero Labs Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Hetero Labs Limited

MSME Payment Delays by Hetero Labs Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Hetero Labs Limited

Subsidiaries & Group Companies of Hetero Labs Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Hetero Labs Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Hetero Labs Limited

MCA Filings & Documents of Hetero Labs Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Hetero Labs Limited

Charges
31 Jan 2026
A charge with Others amounted to Rs. 0.30 Cr with Charge ID 101238989 was registered on 31 Jan 2026.
Charges
23 Jan 2026
A charge with Others amounted to Rs. 0.15 Cr with Charge ID 101235216 was registered on 23 Jan 2026.
Charges
31 Dec 2025
A charge with Others amounted to Rs. 0.10 Cr with Charge ID 101224720 was registered on 31 Dec 2025.
Charges
30 Dec 2025
A charge with Others amounted to Rs. 0.64 Cr with Charge ID 101222068 was registered on 30 Dec 2025.
Charges
20 Dec 2025
A charge with Others amounted to Rs. 0.20 Cr with Charge ID 101224826 was registered on 20 Dec 2025.
Directors
18 Dec 2025
Kshitiz Gadodia was appointed as a Cfo on 18 Dec 2025 & has been associated with this company since 6 months 24 days.

Recent News on Hetero Labs Limited

Frequently Asked Questions about Hetero Labs Limited

Hetero Labs Limited is an active public limited company in the pharma sector based in Balanagar, Telangana, India. It was incorporated on 10 March 1989 (37+ years old) and is registered under CIN U24110TG1989PLC009723. The company has 7,319 employees.

Hetero Labs Limited reported revenue of ₹16,537 Cr for FY 2025 (up 13.00% YoY).

The current directors of Hetero Labs Limited are:

The primary industry of Hetero Labs Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Hetero Labs Limited can be reached at the registered office: #7 – 2 – A2, Industrial Estate Sanath Nagar, Balanagar, Telangana, India – 500018, or through the website hetero.com.

The authorised capital is ₹320 Cr, and the paid-up capital is ₹277.06 Cr.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available